MedTrace Logo

HEAL-LAA Clinical Trial

NCT05809596 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 949

Last updated 2025-11-04

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.

Conditions

Interventions

DEVICE

WATCHMAN FLX Pro LAAC Device

Treatment with a WATCHMAN FLX Pro Left Atrial Appendage Closure Device

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Mohamed Kanj, MD · The Cleveland Clinic

  • Oluseun Alli, MD · Novant Health Heart & Vascular Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2024-07-15
Completion
2025-09-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05809596 on ClinicalTrials.gov